1 / 30

Giovanni Battista Gaeta Unità Epatiti Virali Acute e Croniche Seconda Università di Napoli

Paestum, 18 maggio 2006. Il portatore di HBV: inattivo o malato ?. Giovanni Battista Gaeta Unità Epatiti Virali Acute e Croniche Seconda Università di Napoli. Il progresso nella definizione della malattia da HBV. Anni ’50-’60 ’60 ’70 ‘90 2000.

bunny
Download Presentation

Giovanni Battista Gaeta Unità Epatiti Virali Acute e Croniche Seconda Università di Napoli

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Paestum, 18 maggio 2006 Il portatore di HBV: inattivo o malato ? Giovanni Battista Gaeta Unità Epatiti Virali Acute e Croniche Seconda Università di Napoli

  2. Il progresso nella definizione della malattia da HBV Anni ’50-’60 ’60 ’70 ‘90 2000 ALT (epatite post-trasfusionale a lunga incubazione, evoluzione in cronicità) HBsAg (Antigene Australia) Istologia (Desmet, 1973) Biologia Molecolare Alta sensibilità

  3. The “healthy carrier”: the histology era de Franchis et al. Ann Intern Med 1993; 118:191-194 Baseline: 92 pts, HBsAg positive blood donors, normal ALT Follow-up: mean 130 mo., 68 pts; 21 with biopsy HBV-DNA: spot-dot hybridization

  4. No Caption Found Characteristics at the baseline HBV-DNA : 10/60

  5. End of follow-up

  6. Limits of a healthy carrier definition based on liver histology and low sensitivity DNA testing • Dependent upon: • Length of biopsy – 20mm optimal • Number of biopsies performed • Type of biopsy needle used • Pathologist experience • HBV-DNA testing: • Spot-dot hybridizazion reveals pg of DNA • Subjective lecture

  7. 1 1 10 10 102 102 103 103 104 104 105 105 106 106 107 107 108 108 109 109 1010 1010 HBVDNA cp/mL HBV DNA IU/mL Available HBV DNA Assays Real Art HBV LC PCR Artus Biotech Digene Corp. HBV Digene Hybrid-Capture I HBV Digene Hybrid-Capture II Ultra-Sensitive Digene Hybrid-Capture II Amplicor HBV Monitor Roche MolecularSystems Cobas Amplicor HBV Monitor Cobas Taqman 48 HBV Versant HBV DNA 1.0 NA Bayer Corp. Versant HBV DNA 3.0 Locarnini et al., Antiv.Therapy 2004

  8. The era of molecular biology Few copies of HBV-DNA can be detected (10 –102) What the clinical significance ? infection/disease

  9. Standardisation of Nomenclature for Hepatitis B (EASL consensus conference September 2002) Inactive HBsAg carrier • Presence of HBsAg and anti-HBe in serum • Serum HBV DNA < 105 copies/ml • Persistently normal serum ALT > 6 months • Liver histology (not essential) HAI grade < 3

  10. 1 1 10 10 102 102 103 103 104 104 105 105 106 106 107 107 108 108 109 109 1010 1010 HBVDNA cp/mL HBV DNA IU/mL Available HBV DNA Assays Real Art HBV LC PCR Artus Biotech Digene Corp. HBV Digene Hybrid-Capture I HBV Digene Hybrid-Capture II Ultra-Sensitive Digene Hybrid-Capture II Amplicor HBV Monitor Roche MolecularSystems Cobas Amplicor HBV Monitor Cobas Taqman 48 HBV Versant HBV DNA 1.0 NA Bayer Corp. Versant HBV DNA 3.0 Locarnini et al., Antiv.Therapy 2004

  11. Serum HBV DNA and Liver Inflammation in Chronic Hepatitis B Review of 26 prospective studies Correlation between HAI and HBV DNA in untreated patients (r=0.78; P=0.0001) Mommeja-Marin H, et al. Hepatology. 2003:37:1309-1319.

  12. Correlation between change in HBV DNA and HAI with treatment Review of 26 prospective studies (r=0.96; P<0.0000) Mommeja-Marin H, et al. Hepatology. 2003:37:1309-1319.

  13. Natural history of inactive HBsAg carriersIncidence per 100 person years of major events NR = not reported

  14. Survival in HBsAg carriers and controls patients= 296 controls = 157 Manno et al., Gastroenterology 2004;127:756-763

  15. Percentage of patients who cleared HBsAg Manno et al., Gastroenterology 2004;127:756-763

  16. Chronic HBsAg carriers: HBV DNA level 1010 109 108 107 106 105 104 103 102 CHB HBeAg + CHB HBeAg – Serum HBV DNA (copies/mL) Inactive Patients Villeneuve JP et al. Gastroenterology 1994. Martinot –Peignoux M et al. J.Hepatol 2002. Hsu et al Hepatology 2002. Mommeja-Marin H et al. Hepatology 2003; Manno,Gastroenterology 2004.

  17. The R.E.V.E.A.L. – HBV STUDY Risk Evaluation of Viral Load Elevation and Associated Liver Disease 23,820 enrolled in 1991-1992 19,665 HBsAg negative 4,155 HBsAg positive 3,851 HBV-DNA tested 3,774 included in the analysis 395 with cirrhosis Chen CJ, EASL Meeting 2005, Abs.#476

  18. Cumulative incidence of cirrhosis N = 3582 P <0.001 Log rank test Iloeje et al, Gastroenterology 2006; 130:678-686

  19. Cumulative incidence of hepatocellular carcinoma HBeAg negative with normal ALT at Baseline n= 2925 Chen CJ, JAMA 2006; 295:65-73

  20. months ALT flares in chronic hepatitis B ALT IU/l

  21. HBV-DNA, ALT and IgM anti-HBc in 40 hepatitis exacerbations in 23 HBV carriers HBV-DNA increments preceded or were simultaneous to ALT elevations in 96.2% of cases. The ALT flares preceded or were simultaneous to IgM anti-HBc increments in 96.2% of cases Colloredo Mels G., 1994

  22. Classification of inactive carrier vs. chronic hepatitis Correct Sensitivity Specificity classification • HBV DNA >vs < 30.000 cp • HBV DNA >vs < 100.000 cp anti-HBc IgM >vs < 0.200 DNA + IgM 80.0 68.0 56.0 92.0 100.0 100.0 91.6 91.9 94.3 90.8 81.6 92.0 Manesis, Am J Gastro 2003

  23. Inactive HBV carriers in Central Italy 705 HBsAg positive subjects in 18 Centers 202 inactive carriers (29%) 84 follow-up (6 mo.) 12% DNA increase >1 log 6.6% ALT elevation 1 anti-HBs seroconversion Piccolo et al, EASL 2006, abs. # 469

  24. Outcome of anti-HBe pos chronic hepatitis B 102 Patients with chronic hepatitis at histology Median follow-up 6 years (2-12) • Progression to cirrhosis • 2-5%/yr in HBeAg positive patients • 8-10% in HBeAg neg • Predictors: older age, alcohol, coinfections, • recurrent flares, bridging necrosis, • fibrosis stage, genotype(?) cirrhosis 49.2% cirrhosis 6.2% From: Brunetto, 2002

  25. Outcome of HBsAg/anti-HBe pos cirrhosis • Hepatic decompensation • 3%/yr • 47% with ascites • 12% jaundice • 9% variceal bleeding • 30% more than one no. = 62 Median follow-up 6 years (2-12) cirrhosis at baseline Hepatocellular carcinoma without cirrhosis < 0.2%/yr (Western areas) 0.6% in Asia with cirrhosis > 2.0%/yr Predictors: older age, male gender, alcohol, environmental factors, coinfections, genotype 10 HCC 9 terminal events worsened 22% From: Brunetto, 2002

  26. Cofactors influencing the outcome of inactive HBV carriers • HCV coinfection • HDV coinfection • HIV coinfection • Alcohol abuse, • steroids, • immunosuppression

  27. HCV wide range 20% significant 20-30% progression HBV <104 cp/ml minimal, inactive fibrosis stable viraemia liver histology outcome The “healthy” carrier ( inactive with chronic HBV; PNAL with chronic HCV) case-definition sensitive

  28. A new type of HBV carrier: The occult carrier

  29. Occult HBV infection HBV-DNA detectable in liver tissue (± serum) by PCR based methods following disappearance of HBsAg in serum 30% in HCV chronic infections 60% in HBsAg negative hepatocellular carcinoma Torberson & Thomas, Lancet Infect Dis, 2002 Pollicino et al, Gastroenterology, 2004

  30. Il portatore di HBV: inattivo o malato ? Paziente HBsAg positivo con ALT normali: • HBV-DNA>10,000 cp/ml = area rischio (2000 IU/ml) • Seguire per un anno ad intervalli di 3 mesi ALT, anti-HBc IgM, HBV-DNA • Biopsia epatica nei casi dubbi

More Related